


IN THE CLAIMS


This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (previously presented): A 5,11-Dihydrodiaryl[b,e][1,4]oxazepine represented by the following formula [I], a stereoisomer thereof, a pharmacologically acceptable salt thereof, or a hydrate thereof:



wherein rings G, J and K each represent benzene ring or a nitrogen-containing aromatic ring; each of R1, R2, R3, R4, R5, R6, R7, and R8 may be the same or different from one another and they each represent a halogen atom or hydrogen atom, each of R9, R10, R11, R12, and R13 may be the same or different from one another and they each represent a hydrogen atom, a halogen atom, cyano group, hydroxyl group, a lower alkyl group, a lower alkoxy group,

amino group, a lower alkylamino group, a lower acylated amino group, a lower acylated lower alkylamino group, a lower dialkylamino group or a cycloalkylamino group, or R9 and R10 or R10 and R11 together form $-O(CH_2)_{n'}O-$ group wherein n' is 1, 2 or 3; A represents CH_2 , $CHOH$, CO or O ; B represents CH_2 , $CHOH$ or CO ; or A-B represents $CH=CH$, D represents CH_2 , CH_2-CH_2 or $CH_2-CH_2-CH_2$ or B-D represents CH_2 ; X and z are bonded together to form CH_2-CH_2 or $CH_2-CH_2-CH_2$ and, in this case, Y represents a hydrogen atom; or Y and z are bonded together to form $CH_2-CH_2-CH_2$ or $CH_2-CH_2-CH_2-CH_2$ and, in this case, X represents a hydrogen atom; and when X and z, and Y and z are not bonded together, X and Y each represent a hydrogen atom and z represents a lower alkyl group; provided that when any of R9, R10, R11, R12, and R13 represents a cyclic amino group of the following formula [E], each of R1, R2, R3, R4, R5, R6, R7, and R8 may be a halogen atom or hydrogen atom but when none of R9, R10, R11, R12, and R13 is a cyclic amino group of formula [E], one or two of R1, R2, R3, R4, R5, R6, R7, and R8 represent a halogen atom and the others represent a hydrogen atom:



[E]

wherein n and m each represent 1 or 2, and W represents carbon atom, or nitrogen which may be substituted with a lower alkyl group, or oxygen, or sulfur atom.

Claim 2 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1 wherein rings G and J are both benzene rings.

Claim 3 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1 wherein either ring G or J is pyridine ring and the other is benzene ring.

Claim 4 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to any one of claims 1 to 3 wherein ring K is benzene ring.

Claim 5 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to any one of claims 1 to 3 wherein ring K is pyridine ring, pyrimidine ring, pyrazine ring or pyridazine ring.

Claim 6 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1 wherein rings G, J and K are benzene rings.

Claim 7 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein X and z are bonded together to form CH₂-CH₂ or CH₂-CH₂-CH₂ and Y represents a hydrogen atom.

Claim 8 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein Y and z are bonded together to form CH₂-CH₂-CH₂ or CH₂-CH₂-CH₂-CH₂ and X represents a hydrogen atom.

Claim 9 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein X and Y are each a hydrogen atom and z represents a lower alkyl group.

Claim 10 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein either or both of R10 and R11 are methoxyl group or R10 and R11 together form methylenedioxy group, and R9, R12 and R13 are each a hydrogen atom.

Claim 11 (currently amended): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein R11 is methoxyl group, and R9, R10, R12 and R13 are each a hydrogen atom.

Claim 12 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein either R10 or R11 is amino group, a lower alkylamino group, a lower acylated amino group, a lower acylated lower alkylamino group, a lower dialkylamino group or a cycloalkylamino group, and the other is a hydrogen atom.

Claim 13 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein either R10 or R11 is a cyclic amino group represented by formula [E] and the other is a hydrogen atom.

Claim 14 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 13 wherein all of R1 to R8 are a hydrogen atom.

Claim 15 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein one of R1, R2, R3, R4, R5, R6, R7, and R8 is fluorine atom or chlorine atom and the other is a hydrogen atom.

Claim 16 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein one of R2, R3, R6 and R7 is fluorine atom or chlorine atom and others are each a hydrogen atom.

Claim 17 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1, wherein A and B-D are both CH₂.

Claim 18 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of R.

Claim 19 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 7 wherein the carbon atom to which X is bonded has an absolute configuration of S.

Claim 20 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of R.

Claim 21 (previously presented): The 5,11-dihydrodiaryl[b,e][1,4]oxazepine, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 8 wherein the carbon atom to which Y is bonded has an absolute configuration of S.

Claim 22 (previously presented): A pharmaceutical composition, which comprises at least one 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 1 and at least one pharmaceutically acceptable carrier.

Claim 23 (previously presented): A pharmaceutical composition, which comprises at least one 5,11-dihydrodiaryl[b,e][1,4]oxazepine, stereoisomer thereof, pharmacologically acceptable salt thereof, or hydrate thereof according to claim 6 and at least one pharmaceutically acceptable carrier.

Claim 24 (previously presented): A method for treating a functional disease of the digestive tract, said method comprising administering an effective amount of a 5,11-dihydrodiaryl[b,e][1,4]oxazepine, a stereoisomer thereof, a pharmacologically acceptable salt thereof or a hydrate thereof according to claim 1 to a subject in need thereof,

wherein said functional disease of the digestive tract is selected from the group consisting of irritable bowel syndrome, rumination syndrome, globus syndrome, functional heart burn, functional chest pain of presumed esophageal origin, functional gastrointestinal disorder, functional dysphagia, functional vomiting, deglutition disorder, aerophagia, functional constipation, functional abdominal bloating, functional abdominal pain syndrome, functional diarrhea, sphincter of Oddi's dysfunction, gallbladder dysfunction, levator ani syndrome, functional fecal incontinence, pelvic floor dyssynergia proctalgia fugax, and a pediatric gastrointestinal function disorder.

Claim 25 (previously presented): The method according to claim 24, wherein said functional disease of the digestive tract is irritable bowel syndrome.

Claims 26-37 (canceled).

Claim 38 (previously presented): The method according to claim 24, wherein said pediatric gastrointestinal function disorder is selected from the group consisting of infant regurgitation syndrome, infant rumination syndrome, cyclic vomiting syndrome, functional gastrointestinal disorders, irritable bowel syndrome, functional abdominal pain, paroxysmal abdominal pain, aerophagia, functional diarrhea, infant dyschezia, functional constipation, functional fecal retention, and functional non-retentive fecal soiling.